SCHEMBL866526

SCHEMBL866526

CC(=O)CCCN1CCOCC1

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PAOX Q6QHF9 2/20 0.71
GLA P06280 1/20 0.55
SMN1; SMN2 Q16637 3/20 0.50
KEAP1 Q14145 1/20 0.50
ALDH1A1 P00352 5/20 0.49
GAA P10253 1/20 0.49
LMNA P02545 2/20 0.47
KDM4E B2RXH2 2/20 0.47
RAB9A P51151 2/20 0.47
NPC1 O15118 1/20 0.47
TP53 P04637 1/20 0.47
HPGD P15428 1/20 0.46
DUSP3 P51452 1/20 0.46
MAPK1 P28482 1/20 0.45
HIF1A Q16665 1/20 0.45
MAPT P10636 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10266874 0.94 PAOX (0.73) PAOXGLASMN1; SMN2KEAP1ALDH1A1
SCHEMBL13135991 0.92 PAOX (0.77) PAOXGLASMN1; SMN2KEAP1ALDH1A1
SCHEMBL23373543 0.90 PAOX (0.59) PAOXGLASMN1; SMN2KEAP1ALDH1A1
SCHEMBL1286679 0.88 GLA (0.64) PAOXGLASMN1; SMN2ALDH1A1LMNA
SCHEMBL16816809 0.83 SMN1; SMN2 (0.54) PAOXGLASMN1; SMN2KEAP1ALDH1A1
SCHEMBL18407843 0.82 PAOX (0.51) PAOXGLASMN1; SMN2KEAP1ALDH1A1
SCHEMBL4934924 0.82 GLA (0.57) PAOXGLASMN1; SMN2KEAP1ALDH1A1
SCHEMBL1358701 0.82 KDM4E (0.61) PAOXGLASMN1; SMN2KEAP1ALDH1A1
SCHEMBL465026 0.82 GLA (0.74) PAOXGLASMN1; SMN2KEAP1ALDH1A1
SCHEMBL805269 0.81 CYP1A2 (0.63) PAOXSMN1; SMN2ALDH1A1LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4215188-A1 AN AMINO LIPID, PREPARATION METHOD AND APPLICATION THEREOF Shenzhen MagicRNA Biotechnology Co., Ltd. (CN) 2023-07-26 EP disclosed
US-20180221279-A1 MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES UNIV BRITISH COLUMBIA (CA) 2018-08-09 US disclosed
US-9968554-B2 Modified drugs for use in liposomal nanoparticles THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2018-05-15 US disclosed
EP-2220061-B1 SPIRO-CONDENSED 1, 3, 4-THIADIAZOLE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY MERCK SHARP & DOHME (US) 2016-02-17 EP disclosed
US-20140356417-A1 MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2014-12-04 US disclosed
US-8822444-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-02 US disclosed
US-8796460-B2 Compounds for inhibiting KSP kinesin activity Mercky Sharp & Dohme Corp. (US) 2014-08-05 US disclosed
US-8790691-B2 Modified drugs for use in liposomal nanoparticles THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2014-07-29 US disclosed
US-8790691-B2 Modified drugs for use in liposomal nanoparticles THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2014-07-29 US disclosed
US-8568772-B2 Modified drugs for use in liposomal nanoparticles THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-10-29 US disclosed
US-20090156572-A1 Nitrogen-containing heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED 2009-06-18 US disclosed
US-20090156572-A1 Nitrogen-containing heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED 2009-06-18 US disclosed
WO-2009072643-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-11 WO disclosed
WO-2009061597-A1 COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY SCHERING CORPORATION (US) 2009-05-14 WO disclosed
WO-2009061595-A1 COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY SCHERING CORPORATION (US) 2009-05-14 WO disclosed
WO-2009052288-A1 SPIRO-CONDENSED 1, 3, 4-THIADIAZOLE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY SCHERING CORPORATION (US) 2009-04-23 WO disclosed
US-20070276017-A1 Thiadiazoline Derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2007-11-29 US disclosed
US-20070276017-A1 Thiadiazoline Derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2007-11-29 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276017-A1 Thiadiazoline Derivative BRD7, NR3C2, NR5A2 PAOX 3546/4885GLA 4127/4885SMN1; SMN2 4003/4885
US-20180221279-A1 MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES ABCB11, SLC47A1, ABCB1 PAOX 2984/4885GLA 1510/4885SMN1; SMN2 985/4885
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 PAOX 485/4885GLA 4021/4885SMN1; SMN2 4533/4885
US-20140356417-A1 MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES ABCB11, SLC47A1, ABCB1 PAOX 2984/4885GLA 1510/4885SMN1; SMN2 985/4885
US-20090156572-A1 Nitrogen-containing heterocyclic compound and use thereof NTSR2, NTSR1, HNMT PAOX 3243/4885GLA 4425/4885SMN1; SMN2 1425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.